Stock PSTV PLUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
2.16 USD 0.00% Intraday chart for Plus Therapeutics, Inc. +7.46% +23.42%
05-09 Transcript : Plus Therapeutics, Inc. - Special Call
05-09 Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
AQ
Plus Therapeutics : Material Agreement - Form 8-K
PU
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
AQ
Transcript : Plus Therapeutics, Inc. - Special Call
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC
CI
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
AQ
Plus Therapeutics : The use of CNSide in Clinical Management of LMD
PU
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
AQ
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC
CI
Plus Therapeutics : Nuclear Medicine and Neurooncology (NMN) Symposium 2024
PU
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense
MT
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
AQ
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense
CI
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
AQ
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AQ
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
AQ
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic
CI
Plus Therapeutics : March 2024 Corporate Presentation
PU
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
AQ
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTV Stock
  4. News Plus Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW